Preservation media, durations and cell concentrations of short-term storage affect key features of human adipose-derived mesenchymal stem cells for therapeutic application.

Fengli Zhang, Huaijuan Ren, Xiaohu Shao, Chao Zhuang, Yantian Chen, Nianmin Qi
Author Information
  1. Fengli Zhang: Cell Culture and Bioprocess Engineering Lab, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
  2. Huaijuan Ren: Cell Culture and Bioprocess Engineering Lab, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
  3. Xiaohu Shao: China Stem Cell Therapy Co., Limited, Shanghai, China.
  4. Chao Zhuang: Cell Culture and Bioprocess Engineering Lab, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
  5. Yantian Chen: Cell Culture and Bioprocess Engineering Lab, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
  6. Nianmin Qi: Cell Culture and Bioprocess Engineering Lab, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.

Abstract

BACKGROUND: Adipose-derived mesenchymal stem cells (ADSCs) have shown great potential in the treatment of various diseases. However, the optimum short-term storage condition of ADSCs in 2∼8 °C is rarely reported. This study aimed at optimizing a short-term storage condition to ensure the viability and function of ADSCs before transplantation.
METHODS: Preservation media and durations of storage were evaluated by cell viability, apoptosis, adhesion ability and colony-forming unit (CFU) capacity of ADSCs. The abilities of cell proliferation and differentiation were used to optimize cell concentrations. Optimized preservation condition was evaluated by cell surface markers, cell cycle and immunosuppressive capacity.
RESULTS: A total of 5% human serum albumin in multiple electrolytes (ME + HSA) was the optimized medium with high cell viability, low cluster rate, good adhesion ability and high CFU capacity of ADSCs. Duration of storage should be limited to 24 h to ensure the quality of ADSCs before transplantation. A concentration of 5 × 10 cells/ml was the most suitable cell concentration with low late stage apoptosis, rapid proliferation and good osteogenic and adipogenic differentiation ability. This selected condition did not change surface markers, cell cycle, indoleamine 2, 3-dioxygenase 1 (IDO1) gene expression and kynurenine (Kyn) concentration significantly.
DISCUSSION: In this study, ME + HSA was found to be the best medium, most likely due to the supplement of HSA which could protect cells, the physiological pH (7.4) of ME and sodium gluconate ingredient in ME which could provide energy for cells. Duration should be limited to 24 h because of reduced nutrient supply and increased waste and lactic acid accumulation during prolonged storage. To keep cell proliferation and limit lactic acid accumulation, the proper cell concentration is 5× 10 cells/ml. Surface markers, cell cycle and immunosuppressive capacity did not change significantly after storage using the optimized condition, which confirmed our results that this optimized short-term storage condition of MSCs has a great potential for the application of cell therapy.

Keywords

References

  1. PeerJ. 2016 Mar 22;4:e1773 [PMID: 27019778]
  2. Transl Res. 2010 Feb;155(2):62-70 [PMID: 20129486]
  3. Stem Cells. 2006 May;24(5):1294-301 [PMID: 16410387]
  4. Eur J Pharm Biopharm. 2013 May;84(1):29-39 [PMID: 23266493]
  5. Stem Cells Dev. 2010 Oct;19(10):1449-70 [PMID: 20486777]
  6. Arch Immunol Ther Exp (Warsz). 2016 Dec;64(6):443-454 [PMID: 27178663]
  7. Biotechnol Lett. 2014 Feb;36(2):201-9 [PMID: 24062136]
  8. Bone Marrow Transplant. 1991 May;7(5):401-3 [PMID: 2070152]
  9. J Biol Chem. 2008 May 9;283(19):13100-7 [PMID: 18334485]
  10. Transfusion. 2009 Jul;49(7):1471-81 [PMID: 19389020]
  11. Biol Blood Marrow Transplant. 2005 May;11(5):389-98 [PMID: 15846293]
  12. Ann Thorac Surg. 1992 Dec;54(6):1126-30 [PMID: 1449297]
  13. J Korean Med Sci. 2006 Dec;21(6):1000-4 [PMID: 17179676]
  14. Eur J Haematol. 2007 Jun;78(6):527-31 [PMID: 17509106]
  15. Acta Pharmacol Sin. 2013 Jun;34(6):747-54 [PMID: 23736003]
  16. Bone Marrow Transplant. 2005 Sep;36(6):561-2 [PMID: 16007104]
  17. J Biomater Appl. 2016 Sep;31(3):317-27 [PMID: 27496540]
  18. Eur J Pharm Biopharm. 2014 Apr;86(3):459-68 [PMID: 24240028]
  19. Neuroscience. 2006;137(2):393-9 [PMID: 16298076]
  20. Cancer Immunol Immunother. 2000 Jun;49(3):152-6 [PMID: 10881694]
  21. Tissue Eng. 2001 Apr;7(2):211-28 [PMID: 11304456]
  22. Haematologica. 2007 Sep;92(9):1208-15 [PMID: 17666368]
  23. Cell Transplant. 2013;22(6):1075-86 [PMID: 23043973]
  24. Curr Stem Cell Res Ther. 2011 Dec;6(4):297-316 [PMID: 21190531]
  25. Acta Haematol. 2009;122(1):1-5 [PMID: 19590176]
  26. Stem Cells Int. 2016;2016:3516574 [PMID: 26880954]
  27. Blood. 2004 Mar 1;103(5):1941-8 [PMID: 14592834]
  28. Bone Marrow Transplant. 2000 Jun;25(12):1299-301 [PMID: 10871736]
  29. Stem Cell Res Ther. 2014 Aug 08;5(4):94 [PMID: 25107289]
  30. Equine Vet J. 2012 Jan;44(1):25-32 [PMID: 21615465]
  31. Int J Cardiol. 2011 Nov 3;152(3):314-20 [PMID: 20674997]
  32. J Tissue Eng Regen Med. 2008 Oct;2(7):436-44 [PMID: 18720444]
  33. Cytotherapy. 2007;9(4):328-37 [PMID: 17573608]
  34. Haematologica. 2009 Oct;94(10):1473-5 [PMID: 19608681]
  35. Stem Cell Rev. 2015 Apr;11(2):298-308 [PMID: 25504377]
  36. Transfusion. 2011 Jan;51(1):137-47 [PMID: 20609197]
  37. J Cell Sci. 2006 Jun 1;119(Pt 11):2204-13 [PMID: 16684817]
  38. Int J Artif Organs. 2010 Jun;33(6):370-80 [PMID: 20669142]
  39. Neurology. 2007 Mar 13;68(11):859-61 [PMID: 17353475]
  40. Biomed Res Int. 2014;2014:951512 [PMID: 24511552]
  41. Ann Neurol. 2005 Jun;57(6):874-82 [PMID: 15929052]
  42. Cytotherapy. 2013 Apr;15(4):460-6 [PMID: 23318345]
  43. Neurology. 2002 Aug 27;59(4):514-23 [PMID: 12196642]
  44. Cryobiology. 1998 Sep;37(2):103-9 [PMID: 9769160]
  45. Arch Iran Med. 2007 Oct;10 (4):459-66 [PMID: 17903050]
  46. Blood. 1984 Aug;64(2):406-14 [PMID: 6430365]
  47. Cryobiology. 2015 Oct;71(2):181-97 [PMID: 26186998]
  48. Glia. 2005 Feb;49(3):407-17 [PMID: 15540231]

Word Cloud

Created with Highcharts 10.0.0cellstorageADSCsconditioncellsshort-termcapacityMEconcentrationmesenchymalstemviabilityPreservationmediaabilityproliferationconcentrationsmarkerscycleHSAoptimizedAdipose-derivedgreatpotentialstudyensuretransplantationdurationsevaluatedapoptosisadhesionCFUdifferentiationsurfaceimmunosuppressivehuman+mediumhighlowgoodDurationlimited24hcells/mlchangesignificantlylacticacidaccumulationapplicationBACKGROUND:showntreatmentvariousdiseasesHoweveroptimum2∼8 °CrarelyreportedaimedoptimizingfunctionMETHODS:colony-formingunitabilitiesusedoptimizeOptimizedpreservationRESULTS:total5%serumalbuminmultipleelectrolytesclusterratequality5× 10suitablelatestagerapidosteogenicadipogenicselectedindoleamine23-dioxygenase1IDO1geneexpressionkynurenineKynDISCUSSION:foundbestlikelyduesupplementprotectphysiologicalpH74sodiumgluconateingredientprovideenergyreducednutrientsupplyincreasedwasteprolongedkeeplimitproper5× 10SurfaceusingconfirmedresultsMSCstherapyaffectkeyfeaturesadipose-derivedtherapeuticCellDurationsShort-term

Similar Articles

Cited By (9)